[Inside Chodong] Drug Pricing System: Normalizing the Abnormal View original image

The government has finalized a sweeping overhaul of the generic drug pricing system—the first such reform in 14 years. The key measure is to gradually lower the maximum price cap for generics, which has been uniformly set at 53.55% of the original drug’s price, to below 45%. Through this, the government aims to save approximately 2.4 trillion won annually in health insurance funds after 10 years, reallocating those resources to the listing of new drugs for rare and severe diseases and to supporting innovative research and development (R&D).


Currently, the price of generic drugs in Korea exceeds double the average of the Organisation for Economic Co-operation and Development (OECD). Compared to Germany, France, and the United Kingdom, it is twice as high, and about 1.5 times higher than in Canada or Japan. This distorted structure—where companies can easily make money simply by producing generics at guaranteed high prices rather than undertaking the difficult path of new drug development—has become entrenched. Generics account for over 80% of all health insurance-covered pharmaceuticals in Korea. The fact that there are as many as 128 generic versions for a single cholesterol-lowering ingredient and 86 for a hypertension medication is a stark embarrassment for the Korean pharmaceutical industry.


This proliferation of generics has inevitably fostered the toxic problem of “rebates.” In a market where differentiation by quality or efficacy is impossible, pharmaceutical companies have relied solely on sales power as their primary means of competition. The reality that a significant portion of revenue is funneled into marketing, with one-third of the industry’s 120,000 employees working in sales promotion, starkly illustrates where the capital of the pharmaceutical sector is leaking.


Therefore, this drug price reduction policy goes beyond a simple administrative measure to cut costs; it is a signal flare for fundamental restructuring to transform the very fabric of the pharmaceutical industry. The industry argues that lower drug prices will undermine R&D momentum. However, even during decades of high generic pricing, R&D investment by domestic listed pharmaceutical companies accounted for just 7.5% (as of 2024), not even half the level of global “big pharma” (21.4% among U.S. pharmaceutical association members). The claim that “profits from generics fund new drug development” is losing credibility.


This overhaul of the drug pricing system marks a critical turning point in safeguarding public health and ensuring the soundness of the national health insurance fund. As Korea becomes an aging society, pharmaceutical expenditures are rising exponentially. There is a growing call to restructure the current insurance system—which is heavily weighted toward coverage for colds and mild illnesses—toward a focus on severe and rare diseases. The savings from lower generic prices must be used to ease access to expensive new drugs for patients whose lives are in immediate danger. Preventing the tragedy of patients forgoing cutting-edge treatments due to cost is, in fact, the essential reason the government manages the drug pricing system in the first place.


Of course, potential side effects from abrupt policy changes must be carefully managed. A robust post-management system is needed to prevent interruptions in the supply of essential medicines due to declining profitability, or the use of substandard raw materials in efforts to cut costs. Sufficient incentives—such as a period of preferential pricing—should be provided to innovative pharmaceutical companies that are sincerely dedicated to R&D, to help ensure a smooth transition.



Now that Korea is aiming to become a “pharmaceutical and bio powerhouse,” abnormally high drug prices and the resulting rebate practices can no longer be sustained. This reform should bring about reduced drug costs for the public, greater access to new drugs for patients, and serve as a catalyst for sweeping innovation across the pharmaceutical industry. We must not forget that indiscriminate protection without discernment will only lead to an overall decline in industry standards.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing